How to Administer Triptorelin
Triptorelin must be administered by a healthcare provider only, with the route and dosing dependent on the clinical indication: intramuscular injection for central precocious puberty, or intramuscular/subcutaneous injection for ovarian suppression in cancer patients.
Administration by Clinical Indication
For Central Precocious Puberty (Pediatric Patients ≥2 years)
Use TRIPTODUR 22.5 mg as a single intramuscular injection once every 24 weeks 1. This is the FDA-approved formulation and schedule for this indication.
Critical administration steps 1:
- Reconstitute the 22.5 mg powder with the co-packaged 2 mL Sterile Water for Injection
- Once mixed, administer immediately without delay
- Inject rapidly in a steady, uninterrupted manner to prevent needle blockage
- Use the provided thin-walled, 21-gauge, 1½" needles
Monitoring requirements 1:
- Check LH levels (via GnRH stimulation test, basal LH, or sex steroid levels) starting 1-2 months after initiation
- Measure height every 3-6 months
- Monitor bone age periodically
- Reassess with each subsequent dose to confirm maintained efficacy
For Ovarian Suppression in Breast Cancer Patients
Administer triptorelin 3.75 mg intramuscularly or subcutaneously every 4 weeks during chemotherapy 2, 3. This dosing was used in the landmark SOFT and TEXT trials that established efficacy for fertility preservation.
Key points for cancer patients:
- Start at least 1 week before chemotherapy begins 3
- Continue throughout the entire duration of chemotherapy
- Can be given via either intramuscular or subcutaneous route with equivalent efficacy 4
The subcutaneous route may cause a palpable, non-irritating 1 cm mass at the injection site that resolves in 8-12 weeks 5. This is benign and expected.
Important Clinical Considerations
Initial Hormonal Surge
Expect an initial rise in gonadotropins and sex steroids during the first 2-4 weeks after the first injection 1. This is due to the initial stimulatory effect before downregulation occurs. Clinical signs of puberty may temporarily worsen during this period in pediatric patients.
Psychiatric Monitoring
Monitor for emotional lability, crying, irritability, impatience, anger, and aggression, as psychiatric events have been reported with GnRH agonists 1.
Neurological Precautions
Watch for seizures (especially in patients with seizure history or CNS abnormalities) and pseudotumor cerebri (monitor for headache, papilledema, blurred vision) 1.
Dosing Variations in Literature
While research shows that lower doses (15-50 mcg daily subcutaneously) can achieve pituitary suppression in IVF protocols 6, 7, and 6-week intervals have been studied in precocious puberty 5, the FDA-approved dosing should be followed: 22.5 mg IM every 24 weeks for pediatric CPP 1 and 3.75 mg IM/SC every 4 weeks for ovarian suppression in cancer 2.
Contraindications
Do not administer in patients with hypersensitivity reactions or during pregnancy 1.